GeneSystem Co

GeneSystem Co Buyback Yield

Buyback Yield of GeneSystem Co (363250.KQ) as of Oct 21, 2026.

Buyback Yield

0.00

Last updated:

Buyback Yield of GeneSystem Co is 2025 0.00 . Buyback Yield of GeneSystem Co was 2024 3.89 % . It decreases by % lower compared to the previous year.

The GeneSystem Co Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
8.94 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
22.65 KRW
Jan 1, 2021
88.37 KRW
Jan 1, 2022
0.67 KRW
Jan 1, 2023
0.72 KRW
Jan 1, 2024
3.89 KRW
Jan 1, 2025
0.00 KRW
The GeneSystem Co Buyback Yield history
YEARBuyback YieldYoY
0.00-100.00%
3.89 %+438.62%
0.72 %+8.09%
0.67 %-99.24%
88.37 %+290.09%
22.65 %—
0.00-100.00%
8.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

On Eulerpool you can find the complete historical development of Buyback Yield GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GeneSystem Co

All Key Metrics — GeneSystem Co